Literature DB >> 24767518

A theoretical analysis showed that blinding cannot eliminate potential for bias associated with beliefs about allocation in randomized clinical trials.

Erin Mathieu1, Robert D Herbert2, Kevin McGeechan3, Jemma J Herbert4, Alexandra L Barratt3.   

Abstract

OBJECTIVES: To explore the theoretical justification for blinding in randomized trials and make recommendations concerning the implementation and interpretation of blinded randomized trials. STUDY DESIGN AND
SETTING: A theoretical analysis was conducted of the potential for bias in randomized trials with successful blinding (ie, trials in which beliefs about allocation to treatment or control groups are independent of actual allocation). The analysis identified conditions that must be satisfied to ensure that blinding eliminates the potential for bias associated with beliefs about allocation.
RESULTS: Even when beliefs about allocation are independent of actual allocation, they can still cause bias. The potential for bias is eliminated when the belief is uniformly one of complete ambivalence about allocation.
CONCLUSION: Even when blinding succeeds in making beliefs about allocation independent of actual allocation, beliefs about allocation may still cause bias. It is difficult to determine the extent of bias in any particular trial. Bias could be eliminated by establishing a state of complete ambivalence about the allocation of every trial participant, but universal ambivalence may be difficult to achieve and may reduce the generalizability of the trial's findings.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bias; Blinding; Clinical trials; Masking; RCTs; Randomized controlled trials

Mesh:

Year:  2014        PMID: 24767518     DOI: 10.1016/j.jclinepi.2014.02.001

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  8 in total

1.  Blinding Assessment: One Step Forward.

Authors:  Jeehyoung Kim; Jongbae J Park; Heejung Bang; Jafar Kolahi
Journal:  Dent Hypotheses       Date:  2021-12-21

Review 2.  Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.

Authors:  Jacob S Aday; Boris D Heifets; Steven D Pratscher; Ellen Bradley; Raymond Rosen; Joshua D Woolley
Journal:  Psychopharmacology (Berl)       Date:  2022-04-01       Impact factor: 4.530

3.  Sample size calculations for blinding assessment.

Authors:  Victoria Landsman; Mark Fillery; Howard Vernon; Heejung Bang
Journal:  J Biopharm Stat       Date:  2017-11-20       Impact factor: 1.051

4.  Safety of low-intensity repetitive transcranial magneTic brAin stimUlation foR people living with mUltiple Sclerosis (TAURUS): study protocol for a randomised controlled trial.

Authors:  Kaylene M Young; Bruce V Taylor; Kalina Makowiecki; Natasha Stevens; Carlie L Cullen; Amin Zarghami; Phuong Tram Nguyen; Lewis Johnson; Jennifer Rodger; Mark R Hinder; Michael Barnett
Journal:  Trials       Date:  2022-08-03       Impact factor: 2.728

5.  Assessing the risk of performance and detection bias in Cochrane reviews as a joint domain is less accurate compared to two separate domains.

Authors:  Ognjen Barcot; Matija Boric; Svjetlana Dosenovic; Livia Puljak
Journal:  BMC Med Res Methodol       Date:  2021-07-18       Impact factor: 4.615

Review 6.  Blinding in Clinical Trials: Seeing the Big Picture.

Authors:  Thomas F Monaghan; Christina W Agudelo; Syed N Rahman; Alan J Wein; Jason M Lazar; Karel Everaert; Roger R Dmochowski
Journal:  Medicina (Kaunas)       Date:  2021-06-24       Impact factor: 2.430

7.  Random Guess and Wishful Thinking are the Best Blinding Scenarios.

Authors:  Heejung Bang
Journal:  Contemp Clin Trials Commun       Date:  2016-05-07

8.  Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression.

Authors:  Johannes A C Laferton; Sagar Vijapura; Lee Baer; Alisabet J Clain; Abigail Cooper; George Papakostas; Lawrence H Price; Linda L Carpenter; Audrey R Tyrka; Maurizio Fava; David Mischoulon
Journal:  Front Psychiatry       Date:  2018-09-07       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.